CROI 2026: Accepted research projects supported by ANRS MIE
CROI, the international Conference on Retroviruses and Opportunistic Infections, will be held from February 22 to 25, 2026, in Denver. Around 20 projects supported by ANRS MIE have been accepted.
Last updated on 23 February 2026
In brief
As every year, CROI will highlight the newest and most consequential research in retroviruses and opportunistic infections.
CROI 2026: Oral presentations of research supported by ANRS MIE
- Intensification of tuberculosis treatment in severely immunocompromised individuals with HIV by François-Xavier Blanc et al, CHU-Nantes
- Nucleocapsid mutations during virological failure of an integrase inhibitor-based regimen by Quentin Le Hingrat et al, Université Paris Cité, AP-HP
- Toward an optimized LAM assays for accurate pediatric tuberculosis diagnosis? by Jean-Pierre Moles et al, université de Montpellier, Inserm
- Final results of the ANRS prevenir study with daily or on demand oral prep with TDF/FTC in Paris, France by Jean-Michel Molina, Université Paris Cité, AP-HP
|
François-Xavier Blanc |
ntensification of tuberculosis treatment in severely immunocompromised individuals with HIV |
|
Jean-Victor Blanc |
Mental health of MSM on PrEP in ANRS PREVENIR study: a group-based trajectory model |
|
Caroline Charre |
Impact of early treatment initiation after perinatal HIV infection on intact provirus levels |
|
Victor Euzen |
Anal microbiome dynamics in MSM of the DEPIST-H/ANRS12400 cohort: HSV-Linked Dysbiosis and HR-HPV Persistence |
|
Fatoumata Fadiga |
Evolution of weight under dual therapy without tenofovir compared to triple therapy: Week 96 results from the MODERATO Trial (ANRS -MIE 12372) |
|
Pierre Frange |
HBV burden and poor vaccine-induced protection in adolescents with HIV-1 in West and Central Africa |
|
Pierre Frange |
Low rate of resistance to dolutegravir in adolescents living with HIV-1 in West and Central Africa |
|
Hegger Fritsch |
Continuous increase in HIV-1 resistance to neutralization by BNABS over the past 30 years |
|
Nour Gazzhaui |
In vitro and in vivo immunogenicity of a dendritic cell-based vaccine targeting HBV epitopes |
|
Jade Ghosn |
HPV prevalence at multiple anatomical sites among transgender people: the PREVHPV-TG ANRS Study |
|
Beatriz Grinsztejn |
Prediction analysis on lesion resolution in people with Mpox: Results from the UNITY open label arm |
|
Quentin Le Hingrat |
Nucleocapsid mutations during virological failure of an integrase inhibitor-based regimen |
|
Alain Makinson |
Neurocognitive decline in PWH with virological response versus controls : the ANRS Aging HAND Study |
|
Jean-Pierre Moles |
Toward an optimized LAM assays for accurate pediatric tuberculosis diagnosis? |
|
Jean-Michel Molina |
Final results of the ANRS prevenir study with daily or on demand oral prep with TDF/FTC in Paris, France |
|
Cathia Soulié |
From widespread use to salvage therapy: Seventeen years of protease inhibitor resistance dynamics |
|
Elisa Teyssou |
In addition to antiviral properties, some antiretrovirals have an anti-NLRP3 inflammasome activity |
|
Camille Vellas |
Dysregulation of the colonic IDO-1/Kynurenine axis in PLWH: Links to dysbiosis and T cell exhaustion |